Canada markets open in 3 hours 32 minutes
  • S&P/TSX

    21,162.65
    +301.55 (+1.45%)
     
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • DOW

    35,719.43
    +492.40 (+1.40%)
     
  • CAD/USD

    0.7913
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    71.49
    -0.56 (-0.78%)
     
  • BTC-CAD

    62,423.88
    -2,898.08 (-4.44%)
     
  • CMC Crypto 200

    1,283.59
    -37.69 (-2.85%)
     
  • GOLD FUTURES

    1,793.50
    +8.80 (+0.49%)
     
  • RUSSELL 2000

    2,253.79
    +50.31 (+2.28%)
     
  • 10-Yr Bond

    1.4800
    0.0000 (0.00%)
     
  • NASDAQ futures

    16,355.25
    +37.25 (+0.23%)
     
  • VOLATILITY

    22.18
    -5.00 (-18.40%)
     
  • FTSE

    7,347.77
    +7.87 (+0.11%)
     
  • NIKKEI 225

    28,860.62
    +405.02 (+1.42%)
     
  • CAD/EUR

    0.7002
    -0.0012 (-0.17%)
     

Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Frequency Therapeutics, Inc. (NASDAQ:FREQ) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

With a market capitalization of US$243m, Frequency Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's delve deeper into each type of owner, to discover more about Frequency Therapeutics.

View our latest analysis for Frequency Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Frequency Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Frequency Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Frequency Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in Frequency Therapeutics. Our data shows that Wasatch Advisors Inc. is the largest shareholder with 9.7% of shares outstanding. BlackRock, Inc. is the second largest shareholder owning 8.9% of common stock, and Federated Hermes, Inc. holds about 5.9% of the company stock. Additionally, the company's CEO David Lucchino directly holds 1.3% of the total shares outstanding.

After doing some more digging, we found that the top 16 have the combined ownership of 51% in the company, suggesting that no single shareholder has significant control over the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Frequency Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Shareholders would probably be interested to learn that insiders own shares in Frequency Therapeutics, Inc.. In their own names, insiders own US$12m worth of stock in the US$243m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, with a 35% stake in the company, will not easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Frequency Therapeutics better, we need to consider many other factors. For example, we've discovered 4 warning signs for Frequency Therapeutics (1 can't be ignored!) that you should be aware of before investing here.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting